SG160424A1 - Compositions of influenza viral proteins and methods of use thereof - Google Patents

Compositions of influenza viral proteins and methods of use thereof

Info

Publication number
SG160424A1
SG160424A1 SG201001924-8A SG2010019248A SG160424A1 SG 160424 A1 SG160424 A1 SG 160424A1 SG 2010019248 A SG2010019248 A SG 2010019248A SG 160424 A1 SG160424 A1 SG 160424A1
Authority
SG
Singapore
Prior art keywords
compositions
methods
influenza viral
viral proteins
fusion proteins
Prior art date
Application number
SG201001924-8A
Other languages
English (en)
Inventor
Thomas J Powell
Valerian Nakaar
Langzhou Song
William F Mcdonald
Duane D Hewitt
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of SG160424A1 publication Critical patent/SG160424A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201001924-8A 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof SG160424A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US63835004P 2004-12-21 2004-12-21
US63825404P 2004-12-21 2004-12-21
US64506705P 2005-01-19 2005-01-19
US65320705P 2005-02-15 2005-02-15
US66687805P 2005-03-31 2005-03-31
US68207705P 2005-05-18 2005-05-18
US74120205P 2005-11-30 2005-11-30

Publications (1)

Publication Number Publication Date
SG160424A1 true SG160424A1 (en) 2010-04-29

Family

ID=36272492

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001924-8A SG160424A1 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Country Status (9)

Country Link
EP (1) EP1831259A2 (es)
JP (1) JP2008524261A (es)
AU (2) AU2005319141B8 (es)
BR (1) BRPI0519705A2 (es)
CA (1) CA2593746A1 (es)
MX (1) MX2007007586A (es)
NZ (1) NZ556004A (es)
SG (1) SG160424A1 (es)
WO (1) WO2006069262A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) * 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US20100068224A1 (en) * 2006-04-24 2010-03-18 Roberto Crea Method for Producing Viral Vaccine and Therapeutic Peptide Antigens
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
PL2173376T3 (pl) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2223934B1 (en) * 2007-11-14 2012-10-03 Institute Of Microbiology, Chinese Academy Of Sciences Polypeptides for inhibiting influenza virus infection
CN104080475A (zh) 2008-04-18 2014-10-01 法克斯因内特公司 鞭毛蛋白的缺失突变体以及使用方法
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
MX348663B (es) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
MX341775B (es) 2010-01-21 2016-09-02 The Texas A&M Univ System * Vectores para vacunas y metodos para potenciar respuestas inmunes.
EP2552490A4 (en) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
US9889189B2 (en) 2012-11-05 2018-02-13 Georgia State University Research Foundation Universal influenza vaccine based on heterologous multiple M2E proteins
RU2571944C1 (ru) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
CA3226951A1 (en) * 2021-09-02 2023-03-09 Grant MCLACHLAN Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688606B (zh) * 2002-08-12 2013-12-25 昆士兰医学研究所理事会 含有辅助t细胞和b细胞表位的新的免疫原性脂肽
US20040223976A1 (en) * 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine

Also Published As

Publication number Publication date
MX2007007586A (es) 2007-12-10
NZ556004A (en) 2010-05-28
AU2005319141A1 (en) 2006-06-29
JP2008524261A (ja) 2008-07-10
EP1831259A2 (en) 2007-09-12
AU2005319141B2 (en) 2010-02-18
WO2006069262A3 (en) 2007-02-01
WO2006069262A2 (en) 2006-06-29
BRPI0519705A2 (pt) 2009-03-10
AU2010200048A1 (en) 2010-01-28
AU2005319141B8 (en) 2010-03-18
CA2593746A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2007053188A3 (en) Production of multivalent virus like particles
FR20C1016I1 (es)
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DE60329983D1 (de) Wachsestersynthase-dna-sequenz, protein und verwendungen davon
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
EP1615945A4 (en) GLYCOPEGYLATION METHOD AND PROTEINS / PEPTIDES PRODUCED THEREFROM
PL1699822T3 (pl) Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
EP1742968A4 (en) IL-13 MUTEIN PROTEINS AND ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
WO2008134697A3 (en) Prrsv vaccins based on gp5 proteins
ATE389397T1 (de) Adjuvante zusammensetzungen
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
NO20040249L (no) Blodgruppeantigenfusjonspolypeptider og fremgangsmater for deres anvendelse
DE60139544D1 (de) Veränderte, fluoreszierende proteine
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2006073422A3 (en) Activation of natural killer (nk) cells and methods of use